Vireo Growth (VREOF) Amortization of Deferred Charges (2021 - 2026)
Vireo Growth (VREOF) reported Amortization of Deferred Charges of $1.1 million for Q1 2026, down 8.33% on a YoY basis from $1.2 million in Q1 2025, and up 31.81% sequentially from $834529.0 in Q4 2025.
Vireo Growth (VREOF) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 6 years of Amortization of Deferred Charges data on file, last reported at $1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges fell 8.33% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (down 4.26% YoY), and the FY2025 full-year result was $3.9 million, down 18.47% from the prior year.
- Amortization of Deferred Charges rose to $1.1 million in Q1 2026, from $834529.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $2.0 million in Q1 2024 to a low of $590240.0 in Q3 2025.
- A 5-year average of $1.3 million and a median of $1.2 million in 2025 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges surged 63.05% in 2022 and sank 52.88% in 2024, its largest moves.
- Tracing VREOF's Amortization of Deferred Charges over 5 years: stood at $1.5 million in 2022, then jumped by 30.12% to $2.0 million in 2023, then sank by 49.55% to $987925.0 in 2024, then declined by 15.53% to $834529.0 in 2025, then surged by 31.81% to $1.1 million in 2026.
- Business Quant data shows VREOF's Amortization of Deferred Charges at $1.1 million in Q1 2026, $834529.0 in Q4 2025, and $590240.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 834,529.00 |
| Dec 31, 2025 | 834,529.00 |
| Sep 30, 2025 | 590,240.00 |
| Sep 30, 2025 | 590,240.00 |
| Jun 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | 1.28 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 987,925.00 |
| Dec 31, 2024 | 987,925.00 |
| Sep 30, 2024 | 889,838.00 |
| Sep 30, 2024 | 889,838.00 |
| Jun 30, 2024 | 900,366.00 |
| Jun 30, 2024 | 900,366.00 |
| Mar 31, 2024 | 2.02 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 1.96 Mn |
| Dec 31, 2023 | 1.96 Mn |